BioCorRx Inc. in Anaheim secured $4.2 million in financing, including $940,000 in equity financing from nine investors and $1.7 million from Alpine Creek Capital, effective by March 24, a press release said.
The company received an initial $2.5 million from Alpine Creek last June.
The funding supports the company in its preclinical studies of BICX101, an injectable naltrexone product intended to treat substance abuse addiction, and to back sales and marketing of the medication-assisted treatment BioCorRx Recovery Program, according to Chief Financial Officer and Chief Operating Officer Lourdes Felix.
BioCorRx Inc. is a wholly owned subsidiary of Fresh Start Private Inc., which changed its name from Fresh Start Private Management Inc. in 2014.
–Sherry Hsieh
